Drug intelligence / Profile preview

KELI-201

Development stage: Preclinical
Lead developer: Keli Therapeutics
Modality: CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Stem Cell Therapies → Cell Therapies

Overview

KELI-201 is an investigational cell therapy being developed by KELI Therapeutics for the treatment of chronic inflammatory and fibrotic diseases. The therapy is based on the KELI-100 platform, utilizing bioreactor-produced placental stromal cells that are genetically modified using CRISPR-Cas9 technology. These modifications involve both gene knock-out and knock-in strategies to enhance the cells' therapeutic potential in addressing tissue damage, immune dysfunction, and persistent inflammation. As of 2025, KELI-201 is in the IND-enabling stage of development, with specific molecular targets and mechanisms of action remaining undisclosed.

Beyond the preview

Go deeper on KELI-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KELI-201.

Explore the full profile